Physician profile
Robert William Duck
NPI 1629160577
$12,025.20
in general payments reported to CMS, 2019-2025
38 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,902 · 2020: $2,043 · 2021: $2,506 · 2022: $1,893 · 2023: $1,527 · 2024: $967 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,682.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,127.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,456.69 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,134.38 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,048.98 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $840.59 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $758.92 | 2019-2025 | Otezla, Repatha, Repatha |
| Merck Sharp & Dohme LLC | $527.30 | 2019-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Glaxosmithkline, LLC. | $384.90 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.63 | 2019-2023 | Jardiance, Tradjenta, Stiolto Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $299.87 | 2019-2025 | Trintellix |
| Sanofi-Aventis U.S. LLC | $288.01 | 2019-2023 | |
| Esperion Therapeutics, INC. | $262.06 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $248.25 | 2019-2023 | Xarelto |
| Abbott Laboratories | $232.73 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Allergan, INC. | $214.92 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Duck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.